Zoetis Posts Mixed Q4 2025 Results Amid Strategic Shifts
Event summary
- Zoetis reported $2.4B in Q4 2025 revenue, up 3% YoY, with organic growth at 4%.
- Full-year 2025 revenue reached $9.5B, up 2% YoY, with organic growth at 6%.
- Q4 U.S. segment revenue declined 2% due to divestitures, while international revenue grew 8%.
- Zoetis received regulatory approvals for Lenivia and Portela, expanding its OA pain franchise.
- The company acquired Veterinary Pathology Group to enhance diagnostic capabilities.
The big picture
Zoetis' Q4 2025 results reflect a mixed performance, with strong international growth offset by U.S. declines due to divestitures. The company's strategic focus on expanding its OA pain franchise and enhancing diagnostic capabilities positions it for long-term innovation, but execution risks remain. The animal health sector continues to prioritize regulatory approvals and operational efficiency as key drivers of sustainable growth.
What we're watching
- Regulatory Momentum
- The pace at which Zoetis can secure additional approvals for Lenivia and Portela in major markets will be critical for sustaining growth in its OA pain franchise.
- International Expansion
- Whether Zoetis can maintain its 8% international revenue growth amid operational changes from the Expected Fiscal Year Alignment.
- Diagnostic Integration
- How effectively Zoetis integrates Veterinary Pathology Group to enhance its diagnostics portfolio and drive higher-margin services.
Related topics